Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Wang A. Z., Lebastchi A. H., O’Connor L. P., Ahdoot M., Mehralivand S., Yerram N., ...Daha Fazla

World Journal of Urology, cilt.39, sa.3, ss.729-739, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s00345-020-03525-0
  • Dergi Adı: World Journal of Urology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Sayfa Sayıları: ss.729-739
  • Anahtar Kelimeler: Focal therapy, prostate cancer, MRI
  • İstanbul Medipol Üniversitesi Adresli: Evet

Özet

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical “middle ground” in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.